$69 postpage LB

Pfizer’s shares plunge after reports of cutting COVID-19 vaccine supply to half

  • December 04, 2020 03:16 PM AEDT
  • Hina Chowdhary
    Director, Equities Research Hina Chowdhary
    1376 Posts

    Hina Chowdhary is the Director, Equity Research at Kalkine and has an extensive experience of about 15 years in the area of Research, which includes 5+ years in Equities Research particularly.She has earned a Master of Science degree from the renowne...

Pfizer’s shares plunge after reports of cutting COVID-19 vaccine supply to half


  • Pfizer shares tumbled after a report stated the company anticipates to roll out half of the COVID-19 vaccines it initially planned.
  • The Company has already signed agreements to supply millions of COVID-19 vaccines and was confident to hit the target.
  • Pfizer and BioNTech anticipates to roll out vaccines post receiving potential regulatory approvals pending across the globe.
Gold MTF non-AMP

Pfizer shares closed the day below 0.22% on Thursday after the news of supply chain challenges. According to several media reports, supply chain challenges forced Pfizer to cut its estimates by half for roll out of the COVID-19 vaccine.

The companies, which announced delivering 100 million doses, are planning to ship 50 million vaccine doses in 2020. Target to ship almost 1.3 billion doses by 2021-end remains the same.

According to media reports, the setbacks in ramping up raw materials, along with an extraordinary attempt to deliver millions of COVID-19 vaccines in less than a year, forced Pfizer to miss the target shipments.

Image source © Kalkine Group

Furthermore, On 2 December 2020, Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) revealed that the MHRA had granted a temporary emergency use authorisation for BNT162b2.  The two companies also revealed to receive further regulatory decisions to come across the globe in the upcoming days and weeks.

The Companies said that they are prepared to provide COVID-19 vaccine doses after the potential regulatory approvals.

Agreements to supply millions of COVID-19 Vaccine Doses

In July 2020, Pfizer and BioNTech revealed an agreement with the UK to supply almost 30 million doses of BNT162b2 after its authorisation for emergency use. That agreement was increased to nearly 40 million doses in early October.

The two companies mentioned that the first doses are anticipated to arrive in the UK in coming days. The companies were expecting to complete delivery fulfilment in 2021.

However, it seems the ongoing supply chain challenges are going to dampen the spirit of the duo.


The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK